Rose McNulty

Adult men with Duchenne muscular dystrophy (DMD) were more than twice as likely to experience fractures compared with adult men without DMD in the UK, a recent study published in Muscle & Nerve found.1 However, less than half of the […]

The FDA today approved the first generic referencing the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (Victoza), an 18 mg/3 mL injection, to improve glycemic control in patients aged 10 years and older with type 2 diabetes.1 The treatment is indicated

In this final part of our recent interview with Ticiana Leal, MD, associate professor and director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine, and a board-certified medical oncologist at Winship

Delivering patient-centered care in the community oncology setting is a multifaceted endeavor, requiring buy-in not only from providers and practices but also from payers and other stakeholders impacting providers’ ability to deliver high-quality care. Collaboration between providers and payers was

Cancer care is constantly evolving, with treatment armamentariums expanding and new data releases coming at an increasing pace. Still, novel therapies are not without their challenges, and questions related to the costs, outcomes, and patient quality-of-life improvements associated with emerging

Continuing our conversation with Ticiana Leal, MD, here she explains the importance of biomarker testing in the perioperative setting for patients who have early-stage non–small cell lung cancer (NSCLC), and how and why conversations across disciplines and during tumor boards

HDP-101, a novel investigational B-cell maturation antigen (BCMA)–targeting antibody-drug conjugate (ADC), demonstrated encouraging efficacy in patients with progressive or refractory multiple myeloma in the phase 1/2a HDP-101-01 trial (NCT04879043). Updated results from the first-in-human, open-label, non-randomized, multicenter study were presented

In the phase 2 FORWARD-53 study (NCT04906460), the investigational exon-skipping oligonucleotide WVE-N531 has shown promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping, according to an interim analysis of the trial. The

Two quadruplet regimens for transplant-eligible newly diagnosed multiple myeloma (NDMM)—daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) and daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd)—showed deep, durable responses in data presented at the 21st International Myeloma Society Annual Meeting & Exposition,